Key Points
- Srinivas Akkaraju, a Kalaris Therapeutics director, purchased 479,847 shares on Dec. 18 at an average price of $10.42, spending about $5.0M and increasing his direct holding to 1,979,847 shares (a 31.99% rise) valued around $20.63M.
- Kalaris has mixed analyst coverage but a consensus "Moderate Buy" with a $14 price target; institutional ownership is high (≈66.05%) and recent institutional buys include Paradigm Biocapital (~$5.91M) and others.
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju acquired 479,847 shares of the stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $10.42 per share, with a total value of $5,000,005.74. Following the transaction, the director directly owned 1,979,847 shares of the company's stock, valued at approximately $20,630,005.74. This trade represents a 31.99% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Kalaris Therapeutics Price Performance
NASDAQ:KLRS opened at $8.27 on Wednesday. The firm's 50-day moving average price is $9.10 and its 200-day moving average price is $6.27. The company has a market capitalization of $154.65 million, a PE ratio of -2.19 and a beta of -0.09. Kalaris Therapeutics Inc. has a 1-year low of $2.14 and a 1-year high of $12.90.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on KLRS. Chardan Capital began coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They set a "buy" rating and a $19.00 target price for the company. Wall Street Zen lowered Kalaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, January 31st. Citigroup reissued an "outperform" rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Citizens Jmp began coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They issued a "market outperform" rating and a $20.00 target price on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $14.00.
Check Out Our Latest Research Report on Kalaris Therapeutics
Institutional Trading of Kalaris Therapeutics
Several institutional investors have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP bought a new stake in shares of Kalaris Therapeutics in the 4th quarter worth $5,908,000. Siren L.L.C. boosted its position in shares of Kalaris Therapeutics by 36.9% during the fourth quarter. Siren L.L.C. now owns 435,798 shares of the company's stock valued at $3,678,000 after buying an additional 117,534 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in Kalaris Therapeutics in the 4th quarter worth about $3,402,000. Woodline Partners LP purchased a new position in Kalaris Therapeutics in the 3rd quarter worth about $1,394,000. Finally, Kalehua Capital Management LLC bought a new position in Kalaris Therapeutics during the 4th quarter valued at about $1,181,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.
Kalaris Therapeutics Company Profile
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
